FDA approves Bristol-Myers' Opdivo for small cell lung cancer


Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France, March 29, 2018.



from Biotech News